BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancerGoldie Y.L. Lui, Carla Grandori, Reid Shaw et al.|EBioMedicine|2020Cited by 38
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testingHeidi J. Gray, Carla Grandori, Payel Chatterjee et al.|npj Precision Oncology|2023Cited by 26
Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck CancerChang Xu, Eduardo Méndez, Carlos L. Green et al.|Clinical Cancer Research|2018Cited by 25
Abstract 1619: Personalized medicine: A CLIA-certified high-throughput drug screening platform for ovarian cancerHallie A. Swan, Carla Grandori, Rachele Rosati et al.|Cancer Research|2018Cited by 5
A cancer organogram test as a guide for oncology treatments in SOLID tumors: An analysis of 628 tests in 419 patients.Astrid Margossian, Carla Grandori, Madison Pollastro et al.|Journal of Clinical Oncology|2021Cited by 4